Latest Biogen News & Updates

See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Biogen

Biopharmaceutical company for neurological, immune, and rare diseases

biogen.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 7,500–10,000

Last updated Today

Latest news about Biogen

In short: Biogen completed a $5.3 billion acquisition of Apellis Pharmaceuticals and reported strong Q1 2026 earnings, despite several new legal challenges.

Company announcements

Yesterday Biogen

Biogen agrees to acquire RayThera for up to $1 billion

The deal adds multiple immunology assets, with a lead candidate poised to enter Phase 1 development in Q3 2026.

June 4 Biogen

Biogen's salanersen receives FDA Breakthrough Therapy Designation for SMA

Designation based on Phase 1b data showing improved motor function in SMA children after gene therapy, addressing unmet needs.

June 1 Biogen

Biogen and UCB announce positive Phase 3 lupus results

The Phase 3 PHOENYCS GO trial met its primary endpoint with statistically significant improvement at Week 48.

May 21 Biogen

Biogen and Denali discontinue BIIB122 after Phase 2b failure

The LUMA study did not meet primary or secondary endpoints in early-stage Parkinson's disease.

Media coverage

Yesterday Reuters

Biogen targets immunology growth with $1 billion RayThera deal | Reuters

Biogen has struck a deal to acquire private biotechnology company RayThera for ‌up to $1 billion, the companies said on Wednesday, as the U.S.-listed drugmaker...

June 16 Yahoo Finance

Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for SKYCLARYS™

Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ (omaveloxolone) have concluded without reaching an agreement.

June 16 FinancialContent

FinancialContent - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB...

June 8 MSN

Biogen's base is declining — but 8 pipeline readouts could flip the story

While Biogen Inc.'s BIIB base business is declining, it is entering a period of pipeline optionality, with eight Phase III ...

Never miss news about Biogen

Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Biogen competitors & trending companies

Browse news for competitors to Biogen and other trending companies.